{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:17:03Z","timestamp":1790997423374,"version":"4.1.0"},"reference-count":49,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","award":["10067758"],"award-info":[{"award-number":["10067758"]}],"id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","award":["10067758"],"award-info":[{"award-number":["10067758"]}],"id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","award":["10067758"],"award-info":[{"award-number":["10067758"]}],"id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["10Z20130012243"],"award-info":[{"award-number":["10Z20130012243"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["10Z20130012243"],"award-info":[{"award-number":["10Z20130012243"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI17C1234"],"award-info":[{"award-number":["HI17C1234"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI17C1234"],"award-info":[{"award-number":["HI17C1234"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI17C1234"],"award-info":[{"award-number":["HI17C1234"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0612-2","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T16:05:47Z","timestamp":1558713947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy"],"prefix":"10.1136","volume":"7","author":[{"given":"Hyun Gul","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Cheol","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Yoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Injung","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Tak","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Chul","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Seong","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0395-2026","authenticated-orcid":false,"given":"Sae Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,5,24]]},"reference":[{"issue":"224","key":"612_CR1","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.","journal-title":"Sci Transl Med"},{"key":"612_CR2","first-page":"91","volume":"7","author":"H Klingemann","year":"2016","unstructured":"Klingemann H, Boissel L, Toneguzzo F. Natural killer cells for immunotherapy - advantages of the NK-92 cell line over. Blood NK Cells Front Immunol. 2016;7:91.","journal-title":"Blood NK Cells Front Immunol"},{"issue":"1","key":"612_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11684-012-0177-7","volume":"6","author":"M Cheng","year":"2012","unstructured":"Cheng M, Zhang J, Jiang W, Chen Y, Tian Z. Natural killer cell lines in tumor immunotherapy. Front Med. 2012;6(1):56\u201366.","journal-title":"Front Med"},{"issue":"8","key":"612_CR4","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","volume":"25","author":"K Rezvani","year":"2017","unstructured":"Rezvani K, Rouce R, Liu E, Shpall E. Engineering natural killer cells for Cancer immunotherapy. Mol Ther. 2017;25(8):1769\u201381.","journal-title":"Mol Ther"},{"issue":"2","key":"612_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jcyt.2016.10.009","volume":"19","author":"S Oelsner","year":"2017","unstructured":"Oelsner S, Friede ME, Zhang C, Wagner J, Badura S, Bader P, et al. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy. 2017;19(2):235\u201349.","journal-title":"Cytotherapy."},{"key":"612_CR6","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3389\/fimmu.2017.00458","volume":"8","author":"M Granzin","year":"2017","unstructured":"Granzin M, Wagner J, Kohl U, Cerwenka A, Huppert V, Ullrich E. Shaping of natural killer cell antitumor activity by ex vivo cultivation. Front Immunol. 2017;8:458.","journal-title":"Front Immunol"},{"key":"612_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3389\/fimmu.2017.00631","volume":"8","author":"JP Veluchamy","year":"2017","unstructured":"Veluchamy JP, Kok N, van der Vliet HJ, Verheul HMW, de Gruijl TD, Spanholtz J. The rise of allogeneic natural killer cells as a platform for Cancer immunotherapy: recent innovations and future developments. Front Immunol. 2017;8:631.","journal-title":"Front Immunol"},{"issue":"4","key":"612_CR8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","volume":"65","author":"G Suck","year":"2016","unstructured":"Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG, et al. NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol Immunother. 2016;65(4):485\u201392.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"612_CR9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrc2355","volume":"8","author":"SA Rosenberg","year":"2008","unstructured":"Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299\u2013308.","journal-title":"Nat Rev Cancer"},{"issue":"19","key":"612_CR10","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-11-1347","volume":"17","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res. 2011;17(19):6287\u201397.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"612_CR11","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","volume":"15","author":"T Tonn","year":"2013","unstructured":"Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013;15(12):1563\u201370.","journal-title":"Cytotherapy."},{"issue":"3","key":"612_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/14653240310001523","volume":"5","author":"YK Tam","year":"2003","unstructured":"Tam YK, Martinson JA, Doligosa K, Klingemann HG. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy. 2003;5(3):259\u201372.","journal-title":"Cytotherapy."},{"issue":"51","key":"612_CR13","doi-asserted-by":"crossref","first-page":"89256","DOI":"10.18632\/oncotarget.19204","volume":"8","author":"BA Williams","year":"2017","unstructured":"Williams BA, Law AD, Routy B, denHollander N, Gupta V, Wang XH, et al. A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. Oncotarget. 2017;8(51):89256\u201368.","journal-title":"Oncotarget."},{"issue":"3","key":"612_CR14","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nprot.2012.016","volume":"7","author":"C Trapnell","year":"2012","unstructured":"Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and cufflinks. Nat Protoc. 2012;7(3):562\u201378.","journal-title":"Nat Protoc"},{"issue":"9","key":"612_CR15","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1186\/gb-2013-14-9-r95","volume":"14","author":"F Rapaport","year":"2013","unstructured":"Rapaport F, Khanin R, Liang Y, Pirun M, Krek A, Zumbo P, et al. Comprehensive evaluation of differential gene expression analysis methods for RNA-seq data. Genome Biol. 2013;14(9):R95.","journal-title":"Genome Biol"},{"issue":"5","key":"612_CR16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nbt.1621","volume":"28","author":"C Trapnell","year":"2010","unstructured":"Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28(5):511\u20135.","journal-title":"Nat Biotechnol"},{"key":"612_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/904767","volume":"2010","author":"CC Uphoff","year":"2010","unstructured":"Uphoff CC, Denkmann SA, Steube KG, Drexler HG. Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines. J Biomed Biotechnol. 2010;2010:904767.","journal-title":"J Biomed Biotechnol"},{"issue":"4","key":"612_CR18","first-page":"652","volume":"8","author":"JH Gong","year":"1994","unstructured":"Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8(4):652\u20138.","journal-title":"Leukemia."},{"issue":"11\u201312","key":"612_CR19","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3727\/096368911X580536","volume":"20","author":"M Cheng","year":"2011","unstructured":"Cheng M, Ma J, Chen Y, Zhang J, Zhao W, Zhang J, et al. Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line. Cell Transplant. 2011;20(11\u201312):1731\u201346.","journal-title":"Cell Transplant"},{"issue":"10","key":"612_CR20","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S0145-2126(03)00024-9","volume":"27","author":"Y Matsuo","year":"2003","unstructured":"Matsuo Y, Drexler HG. Immunoprofiling of cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma. Leuk Res. 2003;27(10):935\u201345.","journal-title":"Leuk Res"},{"issue":"3","key":"612_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1089\/152581601750288975","volume":"10","author":"G Maki","year":"2001","unstructured":"Maki G, Klingemann HG, Martinson JA, Tam YK. Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J Hematother Stem Cell Res. 2001;10(3):369\u201383.","journal-title":"J Hematother Stem Cell Res"},{"key":"612_CR22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3389\/fimmu.2013.00499","volume":"4","author":"M Luetke-Eversloh","year":"2013","unstructured":"Luetke-Eversloh M, Killig M, Romagnani C. Signatures of human NK cell development and terminal differentiation. Front Immunol. 2013;4:499.","journal-title":"Front Immunol"},{"issue":"8","key":"612_CR23","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1182\/blood-2009-11-253286","volume":"116","author":"K Juelke","year":"2010","unstructured":"Juelke K, Killig M, Luetke-Eversloh M, Parente E, Gruen J, Morandi B, et al. CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood. 2010;116(8):1299\u2013307.","journal-title":"Blood."},{"key":"612_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","volume":"31","author":"EO Long","year":"2013","unstructured":"Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol. 2013;31:227\u201358.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"612_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/icb.2013.95","volume":"92","author":"LF Andrade de","year":"2014","unstructured":"de Andrade LF, Smyth MJ, Martinet L. DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins. Immunol Cell Biol. 2014;92(3):237\u201344.","journal-title":"Immunol Cell Biol"},{"key":"612_CR26","doi-asserted-by":"crossref","unstructured":"Gunesch JT, Angelo LS, Mahapatra S, Deering RP, Kowalko JE, Sleiman P, et al. Genome-wide analyses and functional profiling of human NK cell lines. Mol Immunol. 2018.","DOI":"10.1016\/j.molimm.2018.07.015"},{"issue":"7","key":"612_CR27","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3390\/ijms20071671","volume":"20","author":"Sanja Stojanovi\u0107","year":"2019","unstructured":"Stojanovic S, Najman S. The effect of conditioned Media of Stem Cells Derived from lipoma and adipose tissue on Macrophages' response and wound healing in indirect co-culture system in vitro. Int J Mol Sci. 2019;20(7).","journal-title":"International Journal of Molecular Sciences"},{"key":"612_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40409-015-0046-3","volume":"21","author":"A Casella-Martins","year":"2015","unstructured":"Casella-Martins A, Ayres LR, Burin SM, Morais FR, Pereira JC, Faccioli LH, et al. Immunomodulatory activity of Tityus serrulatus scorpion venom on human T lymphocytes. J Venom Anim Toxins Incl Trop Dis. 2015;21:46.","journal-title":"J Venom Anim Toxins Incl Trop Dis"},{"issue":"1","key":"612_CR29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1165\/rcmb.2017-0160TR","volume":"58","author":"O Khoury","year":"2018","unstructured":"Khoury O, Barrios C, Ortega V, Atala A, Murphy SV. Immunomodulatory cell therapy to target cystic fibrosis inflammation. Am J Respir Cell Mol Biol. 2018;58(1):12\u201320.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"612_CR30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrg3185","volume":"13","author":"C Vogel","year":"2012","unstructured":"Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012;13(4):227\u201332.","journal-title":"Nat Rev Genet"},{"issue":"7","key":"612_CR31","doi-asserted-by":"publisher","first-page":"11963","DOI":"10.18632\/oncotarget.14449","volume":"8","author":"S Mustafa","year":"2017","unstructured":"Mustafa S, Pan L, Marzoq A, Fawaz M, Sander L, Ruckert F, et al. Comparison of the tumor cell secretome and patient sera for an accurate serum-based diagnosis of pancreatic ductal adenocarcinoma. Oncotarget. 2017;8(7):11963\u201376.","journal-title":"Oncotarget."},{"issue":"4","key":"612_CR32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1089\/15258160152509145","volume":"10","author":"T Tonn","year":"2001","unstructured":"Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res. 2001;10(4):535\u201344.","journal-title":"J Hematother Stem Cell Res."},{"issue":"6","key":"612_CR33","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/14653240802301872","volume":"10","author":"S Arai","year":"2008","unstructured":"Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008;10(6):625\u201332.","journal-title":"Cytotherapy."},{"issue":"6","key":"612_CR34","doi-asserted-by":"publisher","first-page":"4772","DOI":"10.1074\/jbc.M408356200","volume":"280","author":"EM Grund","year":"2005","unstructured":"Grund EM, Spyropoulos DD, Watson DK, Muise-Helmericks RC. Interleukins 2 and 15 regulate Ets1 expression via ERK1\/2 and MNK1 in human natural killer cells. J Biol Chem. 2005;280(6):4772\u20138.","journal-title":"J Biol Chem"},{"key":"612_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000154856","volume":"94","author":"G Erten","year":"2008","unstructured":"Erten G, Aktas E, Deniz G. Natural killer cells in allergic inflammation. Chem Immunol Allergy. 2008;94:48\u201357.","journal-title":"Chem Immunol Allergy"},{"issue":"6","key":"612_CR36","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.4049\/jimmunol.1201528","volume":"189","author":"SH Lee","year":"2012","unstructured":"Lee SH, Fragoso MF, Biron CA. Cutting edge: a novel mechanism bridging innate and adaptive immunity: IL-12 induction of CD25 to form high-affinity IL-2 receptors on NK cells. J Immunol. 2012;189(6):2712\u20136.","journal-title":"J Immunol"},{"key":"612_CR37","doi-asserted-by":"crossref","unstructured":"Poznanski SM, Ashkar AA. Shining light on the significance of NK cell CD56 brightness. Cell Mol Immunol. 2018.","DOI":"10.1038\/s41423-018-0163-3"},{"issue":"10","key":"612_CR38","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2326-6066.CIR-18-0144","volume":"6","author":"SM Poznanski","year":"2018","unstructured":"Poznanski SM, Nham T, Chew MV, Lee AJ, Hammill JA, Fan IY, et al. Expanded CD56(superbright)CD16(+) NK cells from ovarian Cancer patients are cytotoxic against autologous tumor in a patient-derived xenograft murine model. Cancer Immunol Res. 2018;6(10):1174\u201385.","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"612_CR39","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1172\/JCI90387","volume":"127","author":"JA Wagner","year":"2017","unstructured":"Wagner JA, Rosario M, Romee R, Berrien-Elliott MM, Schneider SE, Leong JW, et al. CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. J Clin Invest. 2017;127(11):4042\u201358.","journal-title":"J Clin Invest"},{"key":"612_CR40","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-014-0080-6","volume":"7","author":"Y Shao","year":"2014","unstructured":"Shao Y, Cheng Z, Li X, Chernaya V, Wang H, Yang XF. Immunosuppressive\/anti-inflammatory cytokines directly and indirectly inhibit endothelial dysfunction--a novel mechanism for maintaining vascular function. J Hematol Oncol. 2014;7:80.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"612_CR41","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1600-0897.2011.00989.x","volume":"66","author":"Anne Braunschweig","year":"2011","unstructured":"Braunschweig A, Poehlmann TG, Busch S, Schleussner E, Markert UR. Signal transducer and activator of transcription 3 (STAT3) and Suppressor of Cytokine Signaling (SOCS3) balance controls cytotoxicity and IL-10 expression in decidual-like natural killer cell line NK-92. Am J Reprod Immunol. 2011;66(4):329\u201335.","journal-title":"American Journal of Reproductive Immunology"},{"issue":"6","key":"612_CR42","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.4049\/jimmunol.138.6.1813","volume":"138","author":"TR Mosmann","year":"1987","unstructured":"Mosmann TR, Yokota T, Kastelein R, Zurawski SM, Arai N, Takebe Y. Species-specificity of T cell stimulating activities of IL 2 and BSF-1 (IL 4): comparison of normal and recombinant, mouse and human IL 2 and BSF-1 (IL 4). J Immunol. 1987;138(6):1813\u20136.","journal-title":"J Immunol"},{"issue":"3","key":"612_CR43","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1089\/hum.2014.069","volume":"26","author":"M Hirvinen","year":"2015","unstructured":"Hirvinen M, Rajecki M, Kapanen M, Parviainen S, Rouvinen-Lagerstrom N, Diaconu I, et al. Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus. Hum Gene Ther. 2015;26(3):134\u201344.","journal-title":"Hum Gene Ther"},{"issue":"20","key":"612_CR44","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1161\/CIRCULATIONAHA.107.740233","volume":"117","author":"A Abbate","year":"2008","unstructured":"Abbate A, Salloum FN, Vecile E, Das A, Hoke NN, Straino S, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation. 2008;117(20):2670\u201383.","journal-title":"Circulation."},{"issue":"12","key":"612_CR45","doi-asserted-by":"publisher","first-page":"6672","DOI":"10.1128\/IAI.70.12.6672-6679.2002","volume":"70","author":"CG Feng","year":"2002","unstructured":"Feng CG, Kullberg MC, Jankovic D, Cheever AW, Caspar P, Coffman RL, et al. Transgenic mice expressing human interleukin-10 in the antigen-presenting cell compartment show increased susceptibility to infection with Mycobacterium avium associated with decreased macrophage effector function and apoptosis. Infect Immun. 2002;70(12):6672\u20139.","journal-title":"Infect Immun"},{"issue":"2","key":"612_CR46","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1042\/BST20150240","volume":"44","author":"A Walker","year":"2016","unstructured":"Walker A, Johnson R. Commercialization of cellular immunotherapies for cancer. Biochem Soc Trans. 2016;44(2):329\u201332.","journal-title":"Biochem Soc Trans"},{"issue":"6","key":"612_CR47","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.jcyt.2015.03.323","volume":"17","author":"H Kim","year":"2015","unstructured":"Kim H, Baptista RP, Trampler F, Zandstra PW, Timmins N. Process development towards efficient large-scale manufacturing of an allogenic natural killer cell therapy. Cytotherapy. 2015;17(6):S11\u2013S2.","journal-title":"Cytotherapy."},{"issue":"1","key":"612_CR48","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00262-017-2055-2","volume":"67","author":"P Nowakowska","year":"2018","unstructured":"Nowakowska P, Romanski A, Miller N, Odendahl M, Bonig H, Zhang C, et al. Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies. Cancer Immunol Immunother. 2018;67(1):25\u201338.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"612_CR49","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1379\/1466-1268(2003)008<0348:HSPRIA>2.0.CO;2","volume":"8","author":"C Gross","year":"2003","unstructured":"Gross C, Schmidt-Wolf IG, Nagaraj S, Gastpar R, Ellwart J, Kunz-Schughart LA, et al. Heat shock protein 70-reactivity is associated with increased cell surface density of CD94\/CD56 on primary natural killer cells. Cell Stress Chaperones. 2003;8(4):348\u201360.","journal-title":"Cell Stress Chaperones"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0612-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0612-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0612-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T21:59:43Z","timestamp":1694901583000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0612-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,24]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["612"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0612-2","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,24]]},"assertion":[{"value":"1 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review of Board (IRB) of the Songeui Campus, College of Medicine, Catholic University of Korea (KIRB-20170523-001). Animal experiments were approved and performed in compliance with the guideline of the Institutional Animal Care and Use Committee (Research-17-09-07).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors from SL BIGEN, Inc. are current or former employees and\/or shareholders of the company. The remaining authors declare no competing financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"138"}}